Our lead development program, ATG-008, is an oral mammalian target of rapamycin (mTOR) kinase inhibitor which inhibits both TORC 1 and 2, and has demonstrated to induce tumor cell apoptosis and decrease tumor cell proliferation.

mTOR, a serine/threonine kinase that is upregulated in a variety of tumors, plays an important role downstream in the PI3K/AKT/mTOR signaling pathway, which is dysregulated in approximately 80% of human cancers.

mTOR links with other proteins and serves as a core component of two distinct protein complexes, mTOR complex 1 and mTOR complex 2, which regulate different cellular processes.

2017 Albert Lasker Basic Medical Research Award was granted to Michael N. Hall, who discovered the nutrient-activated TOR proteins and their central role in the metabolic control of cell growth.

ATG-008 is planned to enter Phase 2/3 clinical study for treatment of solid tumor in Asian countries and regions in 2018.